OVERALL CANCER DEATH RATES DECLINE

FROM 1991-2019 CANCER DEATH RATES DROPPED BY 32% 1

TOP TEN TUMOR TYPES SEEN AT MARY CROWLEY
1. COLON & RECTAL
2. PANCREATIC
3. NON-SMALL CELL LUNG
4. OVARIAN
5. PROSTATE
6. SARCOMA
7. ENDOMETRIAL
8. CHOLANGIOCARCINOMA
9. SMALL-CELL LUNG
10. HEAD & NECK

LEADING GLOBAL PHARMACEUTICAL COMPANIES

1. COLON & RECTAL
2. PANCREATIC
3. NON-SMALL CELL LUNG
4. OVARIAN
5. PROSTATE
6. SARCOMA
7. ENDOMETRIAL
8. CHOLANGIOCARCINOMA
9. SMALL-CELL LUNG
10. HEAD & NECK

MISSION STATEMENT
To bring hope to cancer patients through innovative clinical trials while advancing treatment for patients in the future.

BY THE NUMBERS

18,060,100+ U.S. ADULTS AND CHILDREN ARE CANCER SURVIVORS 1

774 # OF TRIALS MANAGED 1997-2021

7503 # OF PATIENTS ENROLLED 1997-2021

6 MEDICAL DOCTORS
3 INVESTIGATORS

18 MCCR CONTRIBUTED TO THE DEVELOPMENT OF 18 FDA-APPROVED DRUGS

1. BAVENCIO
2. ROZLYTREK
3. LIBTAYO
4. CABOMETYX
5. LYNPARZA
6. NINLARO
7. PROVENGE
8. YERVOY
9. IMLYGIC
10. CAMPOSTAR
11. IMFINZI
12. PEMAZYRE
13. SOTORASIB
14. NIRAPARIB
15. TAZETOMOSTAT
16. ABEMACICLIB
17. LENVIMA
18. YONDELIS

60+ TRIALS OPEN AT ANY GIVEN TIME IN 2021

499 NEW PATIENT REFERRALS

A MESSAGE FROM ROY LAMKIN
Chair of the Board of Directors

Offering HOPE to More Cancer Patients Every Day

2021 saw the continuation of the momentum that our team built in 2020, overcoming the limitations and risks of the COVID-19 pandemic to successfully offer uninterrupted care throughout the pandemic and provide more trials to more patients than ever before.

Because of that success, we were able to focus on the ability to expand our footprint to reach more patients as well as expand our leadership in genomic trials for our patients.

Operationally and financially, we continued to improve our efficiency. Our cash position, along with our emphasis on maximizing the impact of philanthropic gifts, has positioned us well as we look to “hardwire” our processes and procedures in anticipation of developing expansion plans in 2022 for several new “clinic-in-a-clinic” locations throughout the Dallas-Fort Worth metroplex, to be known as the Mary Crowley Site Network.

Organizationally we began a transition to increasing our focus on the exciting and rapidly expanding availability of genomic and other “-omic” based trials. Already a leader in these types of trials, discussions with like-minded oncologists provided Mary Crowley with a strong foundation for our anticipated growth in providing more of them to our patients. Additionally, we began a focused and concentrated approach to develop cancer “clinic-in-a-clinic” concepts at various locations in the Dallas-Ft. Worth metroplex focused on prostate cancer.

2022 will provide us the opportunity to take dramatic steps forward in expanding our ability to offer HOPE to late-stage cancer patients through additional locations and extending our leadership in offering genomic based trials. I encourage you to read some of the personal stories of our patients and caregivers in this report and on our website to better understand the impact that Mary Crowley is having by providing HOPE to cancer patients in the Dallas-Fort Worth metroplex and beyond.
MARY CROWLEY MEDICAL RESEARCH CENTER AND AFFILIATES
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

As of December 31, 2021 and 2020

<table>
<thead>
<tr>
<th>Assets</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$6,995,987</td>
<td>$3,974,872</td>
</tr>
<tr>
<td>Investments in securities</td>
<td>1,779,317</td>
<td>1,496,579</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>5,380,609</td>
<td>5,950,044</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>3,950</td>
<td>72,175</td>
</tr>
<tr>
<td>Prepaid expenses &amp; other current assets</td>
<td>48,414</td>
<td>42,520</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>14,208,277</td>
<td>11,536,190</td>
</tr>
<tr>
<td><strong>PROPERTY AND EQUIPMENT (NET)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OTHER ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deposits</td>
<td>30,432</td>
<td>30,432</td>
</tr>
<tr>
<td><strong>Total other assets</strong></td>
<td>30,432</td>
<td>30,432</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>14,534,956</td>
<td>11,768,380</td>
</tr>
</tbody>
</table>

| Liabilities and Net Assets                 |            |            |
| **CURRENT LIABILITIES**                   |            |            |
| Accounts payable                           | 1,525,265  | 533,726    |
| Accrued expenses                           | 1,462,979  | 717,191    |
| Contract Liabilities                       | 12,000     | 68,469     |
| **Total current liabilities**              | 3,000,244  | 1,319,386  |
| **LONG-TERM LIABILITIES**                 |            |            |
| SBA Loans                                  | 10,000     | 10,000     |
| **Total liabilities**                      | 3,010,244  | 1,329,386  |
| **NET ASSETS**                             |            |            |
| Total Without Donor Restrictions           | 10,131,944 | 8,582,949  |
| Total With Donor Restrictions              | 1,392,768  | 1,856,045  |
| **Total net assets**                       | 11,524,712 | 10,438,994 |
| **TOTAL LIABILITIES AND NET ASSETS**       | 14,534,956 | 11,768,380 |
MARY CROWLEY MEDICAL RESEARCH CENTER AND AFFILIATES
CONSOLIDATED STATEMENT OF ACTIVITIES

For the Year Ended December 31, 2021
With summarized financial information for the year ended December 31, 2020

<table>
<thead>
<tr>
<th>Support and Revenue:</th>
<th>Without Donor Restriction</th>
<th>With Donor Restriction</th>
<th>Total All Funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue - Contracts with customers</td>
<td>$11,593,244</td>
<td>-</td>
<td>10,934,738</td>
</tr>
<tr>
<td>Research revenue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contribution and grant revenue</td>
<td>289,983</td>
<td>1,073,576</td>
<td>939,340</td>
</tr>
<tr>
<td>Interest income</td>
<td>35,465</td>
<td>-</td>
<td>33,322</td>
</tr>
<tr>
<td>PPP loan</td>
<td>-</td>
<td>-</td>
<td>1,237,000</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>41,163</td>
<td>-</td>
<td>20,431</td>
</tr>
<tr>
<td>Unrealized gain (loss) on investments</td>
<td>229,956</td>
<td>-</td>
<td>85,611</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>1,536,853</td>
<td>(1,536,853)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total support and revenue</strong></td>
<td>13,726,664</td>
<td>(463,277)</td>
<td>13,263,387</td>
</tr>
</tbody>
</table>

Operating Expenses:

<table>
<thead>
<tr>
<th>Program</th>
<th>Without Donor Restriction</th>
<th>With Donor Restriction</th>
<th>Total All Funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical &amp; research</td>
<td>9,468,935</td>
<td>-</td>
<td>8,072,388</td>
</tr>
<tr>
<td>General &amp; administrative</td>
<td>2,280,444</td>
<td>-</td>
<td>1,965,576</td>
</tr>
<tr>
<td>Fundraising</td>
<td>435,100</td>
<td>-</td>
<td>389,257</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>12,184,479</td>
<td>-</td>
<td>10,427,221</td>
</tr>
</tbody>
</table>

Changes in net assets from operations                                               | 1,542,185                 | (463,277)              | 2,823,221       |

Other income (expense)                                                              | 6,810                     | -                      | 4,804           |

Change in net assets                                                                 | 1,548,995                 | (463,277)              | 2,828,025       |

Net assets, beginning of period                                                      | 8,582,949                 | 1,856,045              | 7,610,969       |

Net assets, end of period                                                            | 10,131,944                | 1,392,768              | 10,438,994      |
Donor Spotlight: Be the Difference Foundation
Supporting a future for all ovarian cancer patients!

In 2015, Be the Difference Foundation and Mary Crowley Cancer Research came together as partners and have remained so to this day. Both agencies are committed to providing hope to ovarian cancer patients and improving treatment options for the patients that so desperately need them.

Be the Difference Foundation was formed in 2012 by four ovarian cancer survivors, Helen Gardner, Jill Bach, Julie Shrell, and Lynn Lentscher, who share the same passion to Be the Difference in the fight against ovarian cancer. These women experienced firsthand the little hope given for survival when they were diagnosed. Several organizations focus on early detection efforts, but very few organizations provide hope to women in the fight. Be the Difference Foundation was started to give survivors hope: hope for better treatment options; hope for longer remissions, and ultimately hope for a cure.

Just five years after diagnosis, co-founder Helen Gardner lost her cancer battle in August 2014. Be the Difference Foundation is working tirelessly to realize Helen’s dream to make a difference in the fight against ovarian cancer. Their mission is “to create awareness and improve the lives of all people affected by ovarian cancer through education, support and research”.

Since 2015, Be the Difference Foundation has given Mary Crowley more than half a million dollars in financial support to conduct phase I and phase II clinical trials for ovarian cancer. In 2019, the chairman of the Be the Difference Foundation board, Lynn Lentscher, came to Deborah Montonen, Vice President and Chief Development Officer at Mary Crowley, and said she had an idea. That idea was a fashion show and luncheon to support ovarian cancer awareness. These two ladies, sitting at lunch, planned the entire event on the back of a napkin. The result was the inaugural Runway For Hope event.

Runway For Hope is a celebration of those bravely battling ovarian cancer and a rallying cry to support the future of cancer care. The September 2019 event quickly sold out and helped bring awareness to the cause as well as a significant gift to help Mary Crowley Cancer Research open more ovarian cancer clinical trials. “As our inaugural event, there was no question who we wanted as the beneficiary from Runway For Hope,” said Lentscher. “Mary Crowley Cancer Research matches our mission of raising hope and creating awareness for ovarian cancer with a quick and personal response to women facing this insidious disease.” The event was held virtually in 2020 and canceled in 2021 due to the COVID-19 pandemic, but the 2019 event was such a success that it will be repeated annually in the future.

Mary Crowley Cancer Research is grateful for a supporter, partner, and fellow fighter in the battle against ovarian cancer. Montonen, affirms, “because of the great partnership with Be the Difference Foundation, Mary Crowley Cancer Research has been able to serve more ovarian cancer patients by opening more ovarian clinical trials. We are extremely grateful for their support and look forward to this partnership for many years to come.”

From the staff, board, and patients of Mary Crowley Cancer Research, thank you to Be the Difference Foundation for your unwavering support. You are truly making an impact on the lives of cancer patients today and helping to bring new treatment options to ovarian cancer patients in the future!
Jose Perez is a man whose life is guided by Jesus Christ. He was a faithful employee of TXU Energy for the last fourteen years, but before that, he worked as an ordained minister with the Assemblies of God Church for 35 years. In their spare time, Jose and his wife, Yolanda, traveled around the country ministering to people and conducting bible study classes.

He was an avid golfer, and when he was not preaching, he was on the links. Then 18 months ago, Jose was diagnosed with Stage IV lung cancer that had metastasized to his lymph nodes, pelvis, and a cancerous lesion on his spine. Fortunately, for Jose, his doctor was Jairo Olivares who, in addition to seeing patients in his practice, also works at Mary Crowley Cancer Research.

Given the advanced stage of Jose’s cancer, Dr. Olivares immediately prescribed an aggressive line of treatment: Six months of chemotherapy and immunotherapy followed by six weeks of radiation treatments. Jose would spend three days straight at the hospital receiving a double dose of chemotherapy fluid through an IV and immunotherapy. He would rest 21 days, then repeat the treatment. After the chemotherapy treatments, Jose underwent radiation treatments and another round of immunotherapy.

Following months of chemotherapy, immunotherapy, and radiation treatments, the cancer in his lymph nodes was eradicated, and the lesion on his spine went dormant. The tumors in his lung and pelvic cancer shrunk 40 percent, but the side effects of the treatments were harsh. Jose was bloated, weak and he lost his hair. Unfortunately, after three months Jose’s tumors began to grow again.

Dr. Olivares was familiar with trial 19-09 at Mary Crowley that was testing a new immunotherapy drug and referred Jose to see if he qualified.

Jose came to Mary Crowley for a screening, and within two weeks, he enrolled. He began treatments of CTX-471, a drug that stimulates the immune system to attack cancer cells. The treatments helped prevent his cancer from metastasizing and shrunk his lung tumor. In December, after three months of treatment, his tumor had reduced by 15 percent, with minimal side effects. His most recent scan in March 2021 showed his tumor had shrunk an additional 15 percent, again with minimal side effects.

Jose Perez faced cancer with seemingly inexhaustible energy and optimism. He credits his faith, his wonderful wife, Yolanda, and their blended family for giving him the strength to fight. Jose expressed his gratitude to Dr. Olivares and all of the nurses at Mary Crowley saying, “I thank God every day for Mary Crowley Cancer Research. The doctors, the nurses, the staff, all of them have been so wonderful to me.”

He is still on the trial and his life is starting to get back to normal. He and Yolanda have started traveling around the country again, ministering to people. He retired from TXU Energy so he has time to conduct Bible study through Zoom meetings. He is blessed with six children, 17 grandchildren, and four great-grandchildren who they visit as often as they can.

He does have one more goal in mind. “I have not been able to play golf because of pain in my pelvis”, he says, “I want to get back playing regularly. I’m 66 now and I want to shoot my age.”
OUR LEADERSHIP
Roy Lamkin, Interim Chief Executive Officer
Minal Barve, M.D., Executive Medical Director
James Strauss, M.D., Clinical Scientific Director
Deborah Montonen, CFRE, Vice President and Chief Development Officer
Angela Ebel, Vice President of Research Operations
Jeanne Jones, Vice President of Clinical Operations
Jennifer Sala, Vice President of Compliance
Amber Craft, Vice President of Finance

BOARD OF TRUSTEES
Roy Lamkin, Board Chair
Ellen Dearman, Board Vice Chair
    Adil Adi
    Marilyn Augur
    Vincent Bush
    Edwin Flores, J.D., PhD
    Thomas B. Hoyt
    Tom Hulsey
    Michael Kearins
    Ashley Ross, M.D.
    Elizabeth Warner, J.D.

MEDICAL STAFF
Minal Barve, M.D., Executive Medical Director
James Strauss, M.D., Clinical Scientific Director
Reva Schneider, M.D., Physician Investigator
Jairo Olivares, M.D., Physician Investigator
Douglas Orr, M.D., Physician Investigator
Maurizio Ghisoli, M.D., Physician Investigator
Leah Plato, P.A., Associate Director of Clinical and Scientific Operations
Zoey Sayi, Nurse Practitioner
Jennifer Ashun, Nurse Practitioner

Patient Clinic
Medical City Dallas
7777 Forest Lane
Bldg. C Suite 707
Dallas, Texas 75230
972-566-3000

Administration
12222 Merit Drive
Suite 1500
Dallas, Texas 75251
214-658-1999